{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:32:37Z","timestamp":1793413957617,"version":"4.5.0"},"reference-count":133,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["HI 1928\/6-1"],"award-info":[{"award-number":["HI 1928\/6-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["WO 1883\/17-1"],"award-info":[{"award-number":["WO 1883\/17-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG HI 1928\/5-1"],"award-info":[{"award-number":["DFG HI 1928\/5-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.schres.2023.02.015","type":"journal-article","created":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T01:44:30Z","timestamp":1676684670000},"page":"27-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Lorazepam in catatonia \u2013 Past, present and future of a clinical success story"],"prefix":"10.1016","volume":"263","author":[{"given":"Dusan","family":"Hirjak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Fricchione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Christian","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Northoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.schres.2023.02.015_bb0005","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1176\/ajp.145.8.1047","article-title":"Lorazepam: therapeutic for catatonic schizophrenia?","volume":"145","author":"Ahuja","year":"1988","journal-title":"Am. J. Psychiatry"},{"issue":"26","key":"10.1016\/j.schres.2023.02.015_bb0010","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa2211868","article-title":"Haloperidol for the treatment of delirium in ICU patients","volume":"387","author":"Andersen-Ranberg","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.schres.2023.02.015_bb0015","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/BF00449127","article-title":"Neuroendocrine evidence for increased responsiveness of dopamine receptors in humans following electroconvulsive therapy","volume":"76","author":"Balldin","year":"1982","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.schres.2023.02.015_bb0020","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/0004867415582232","article-title":"Treatment refractory chronic catatonia responsive to zolpidem challenge","volume":"50","author":"Bastiampillai","year":"2016","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2023.02.015_bb0025","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/mp.2016.105","article-title":"Inducible ablation of dopamine D2 receptors in adult mice impairs locomotion, motor skill learning and leads to severe parkinsonism","volume":"22","author":"Bello","year":"2017","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2023.02.015_bb1020","first-page":"224","article-title":"The use of sodium amytal in catatonia","volume":"10","author":"Bleckwenn","year":"1931","journal-title":"Assoc. Res. Nerv. Ment. Dis."},{"key":"10.1016\/j.schres.2023.02.015_bb1055","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1176\/ajp.93.4.957","article-title":"Therapy in catatonia","volume":"93","author":"Broder","year":"1937","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2023.02.015_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.674335","article-title":"Excited catatonia in autism Spectrum disorder: a case series","volume":"12","author":"Burns","year":"2021","journal-title":"Front Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2023.02.015_bb0035","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1600-0447.1996.tb09815.x","article-title":"Catatonia. II. Treatment with lorazepam and electroconvulsive therapy","volume":"93","author":"Bush","year":"1996","journal-title":"Acta Psychiatr. Scand."},{"issue":"2","key":"10.1016\/j.schres.2023.02.015_bb1100","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1600-0447.1996.tb09814.x","article-title":"Catatonia. I. Rating scale and standardized examination","volume":"93","author":"Bush","year":"1996","journal-title":"Acta Psychiatr. Scand."},{"issue":"2","key":"10.1016\/j.schres.2023.02.015_bb0040","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1176\/jnp.9.2.303","article-title":"Catatonia due to mixed sedative withdrawal","volume":"9","author":"Carroll","year":"1997","journal-title":"J. Neuropsychiatr. Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.schres.2023.02.015_bb0045","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1185\/03007997209111148","article-title":"Lorazepam and diazepam in severe neurotic illness","volume":"1","author":"Coates","year":"1972","journal-title":"Curr. Med. Res. Opin."},{"issue":"12","key":"10.1016\/j.schres.2023.02.015_bb1040","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1177\/014107680409701214","article-title":"One hundred years of barbiturates and their saint","volume":"97","author":"Cozanitis","year":"2004","journal-title":"J. R. Soc. Med."},{"issue":"3","key":"10.1016\/j.schres.2023.02.015_bb0050","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/BF00210844","article-title":"Differential amnesic properties of benzodiazepines: a dose-response comparison of two drugs with similar elimination half-lives","volume":"92","author":"Curran","year":"1987","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/j.schres.2023.02.015_bb0055","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1176\/jnp.2009.21.4.371","article-title":"Catatonia: clinical aspects and neurobiological correlates","volume":"21","author":"Daniels","year":"2009","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.schres.2023.02.015_bb0060","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1055\/s-2001-15188","article-title":"Benzodiazepine withdrawal-induced catatonia","volume":"34","author":"Deuschle","year":"2001","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"10.1016\/j.schres.2023.02.015_bb0065","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S1388-2457(99)00314-4","article-title":"Direct demonstration of the effect of lorazepam on the excitability of the human motor cortex","volume":"111","author":"Di Lazzaro","year":"2000","journal-title":"Clin. Neurophysiol."},{"issue":"10","key":"10.1016\/j.schres.2023.02.015_bb0070","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00702-010-0467-7","article-title":"Electroconvulsive therapy resolves cortical inhibition and manneristic omissions in a chronic catatonic patient","volume":"117","author":"Dresler","year":"2010","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.schres.2023.02.015_bb1045","first-page":"1279","article-title":"The use and abuse of psychotropic drugs","volume":"63","author":"Dunlop","year":"1970","journal-title":"Proc. R. Soc. Med."},{"issue":"4","key":"10.1016\/j.schres.2023.02.015_bb0075","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1177\/0269881105053313","article-title":"Clozapine monotherapy for catatonic schizophrenia: should clozapine be the treatment of choice, with catatonia rather than psychosis as the main therapeutic index?","volume":"19","author":"Dursun","year":"2005","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2023.02.015_bb0080","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3390\/neurolint13040057","article-title":"Catatonia: clinical overview of the diagnosis, treatment, and clinical challenges","volume":"13","author":"Edinoff","year":"2021","journal-title":"Neurol. Int."},{"key":"10.1016\/j.schres.2023.02.015_bb0085","series-title":"Neuropharmacology: Transactionsof the Third Conference","first-page":"205","article-title":"Effects of psychosomimetic drugs in animals and man","volume":"1957","author":"Elkes","year":"1957"},{"issue":"3","key":"10.1016\/j.schres.2023.02.015_bb0090","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/cpt1971123468","article-title":"Central nervous system and cardiovascular effects of lorazepam in man","volume":"12","author":"Elliott","year":"1971","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.schres.2023.02.015_bb0095","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3389\/fpsyt.2015.00182","article-title":"Neurobiological approach of catatonia and treatment perspectives","volume":"6","author":"Ellul","year":"2015","journal-title":"Front Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2023.02.015_bb0100","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s007020170041","article-title":"Catatonia: syndrome or schizophrenia subtype? Recognition and treatment","volume":"108","author":"Fink","year":"2001","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"11","key":"10.1016\/j.schres.2023.02.015_bb0105","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/archgenpsychiatry.2009.141","article-title":"The catatonia syndrome: forgotten but not gone","volume":"66","author":"Fink","year":"2009","journal-title":"Arch. Gen. Psychiatry"},{"issue":"8","key":"10.1016\/j.schres.2023.02.015_bb0110","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/0006-3223(89)90116-9","article-title":"Catatonia: a new indication for benzodiazepines?","volume":"26","author":"Fricchione","year":"1989","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2023.02.015_bb0115","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/B978-0-444-64196-0.00012-1","article-title":"Cingulate-basal ganglia-thalamo-cortical aspects of catatonia and implications for treatment","volume":"166","author":"Fricchione","year":"2019","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.schres.2023.02.015_bb1035","first-page":"97","article-title":"Ueber eine Klasse von Schlafmitteln","volume":"5","author":"Fischer","year":"1903","journal-title":"TherGegenw"},{"issue":"3","key":"10.1016\/j.schres.2023.02.015_bb0120","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/0006-3223(85)90060-5","article-title":"Neuroleptic catatonia and its relationship to psychogenic catatonia","volume":"20","author":"Fricchione","year":"1985","journal-title":"Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2023.02.015_bb0125","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/00004714-198312000-00002","article-title":"Intravenous lorazepam in neuroleptic-induced catatonia","volume":"3","author":"Fricchione","year":"1983","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2023.02.015_bb0130","first-page":"20","article-title":"Lorazepam treatment of acute and chronic catatonia in two mentally retarded brothers","volume":"55","author":"Gaind","year":"1994","journal-title":"J. Clin. Psychiatry"},{"issue":"3713","key":"10.1016\/j.schres.2023.02.015_bb1030","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/bmj.1.3713.421","article-title":"Pharmacological properties of iso-amyl ethyl barbituric acid (amytal)","volume":"1","author":"Garry","year":"1932","journal-title":"Br. Med. J."},{"issue":"1","key":"10.1016\/j.schres.2023.02.015_bb0135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/YCT.0b013e31819359fc","article-title":"Laszlo Meduna's pilot studies with camphor inductions of seizures: the first 11 patients","volume":"25","author":"Gazdag","year":"2009","journal-title":"J ECT"},{"issue":"3","key":"10.1016\/j.schres.2023.02.015_bb0140","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/0957154X19847605","article-title":"How amytal changed psychopharmacy: off-label uses of sodium amytal (1920\u201340)","volume":"30","author":"Gershon","year":"2019","journal-title":"Hist. Psychiatry"},{"key":"10.1016\/j.schres.2023.02.015_bb0145","series-title":"Lorazepam","author":"Ghiasi","year":"2022"},{"issue":"1","key":"10.1016\/j.schres.2023.02.015_bb0150","first-page":"21","article-title":"Electroconvulsive therapy in lorazepam non-responsive catatonia","volume":"45","author":"Girish","year":"2003","journal-title":"Indian J. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2023.02.015_bb1080","first-page":"1049","article-title":"Pharmacology of 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one","volume":"21","author":"Gluckman","year":"1971","journal-title":"Arzneimittel-Forschung"},{"key":"10.1016\/j.schres.2023.02.015_bb1075","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/jps.3030360103","article-title":"Barbiturates: a blessing and a menace","volume":"6","author":"Goldstein","year":"1947","journal-title":"J. Am. Pharm. Assoc."},{"issue":"6","key":"10.1016\/j.schres.2023.02.015_bb0155","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.psym.2020.05.026","article-title":"Can memantine improve catatonia and co-occurring cognitive dysfunction? A case report and brief literature review","volume":"61","author":"Graziane","year":"2020","journal-title":"Psychosomatics"},{"issue":"2","key":"10.1016\/j.schres.2023.02.015_bb0160","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/jps.2600710227","article-title":"Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam","volume":"71","author":"Greenblatt","year":"1982","journal-title":"J. Pharm. Sci."},{"issue":"24","key":"10.1016\/j.schres.2023.02.015_bb0165","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM197812142992405","article-title":"Prazepam and lorazepam, two new benzodiazepines","volume":"299","author":"Greenblatt","year":"1978","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.schres.2023.02.015_bb0170","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1097\/00003246-200008000-00011","article-title":"Kinetics and dynamics of lorazepam during and after continuous intravenous infusion","volume":"28","author":"Greenblatt","year":"2000","journal-title":"Crit. Care Med."},{"issue":"9","key":"10.1016\/j.schres.2023.02.015_bb0175","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1176\/ajp.144.9.1224","article-title":"Treatment of catatonia with low-dose lorazepam","volume":"144","author":"Greenfeld","year":"1987","journal-title":"Am. J. Psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2023.02.015_bb0180","first-page":"767","article-title":"The therapeutic effects of lorazepam in psychotic patients treated with haloperidol: a double-blind study","volume":"14","author":"Guz","year":"1972","journal-title":"Curr. Ther. Res. Clin. Exp."},{"issue":"553","key":"10.1016\/j.schres.2023.02.015_bb1090","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1192\/bjp.119.553.599","article-title":"A comparative trial of lorazepam and diazepam","volume":"119","author":"Haider","year":"1971","journal-title":"Br. J. Psychiatry\u202f: J. Ment. Sci."},{"issue":"2","key":"10.1016\/j.schres.2023.02.015_bb0185","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1185\/03007997209111147","article-title":"Lorazepam in the treatment of anxiety","volume":"1","author":"Haider","year":"1972","journal-title":"Curr. Med. Res. Opin."},{"issue":"6","key":"10.1016\/j.schres.2023.02.015_bb0190","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/archneur.1989.00520420118033","article-title":"Benzodiazepine withdrawal delirium with catatonic features. Occurrence in patients with partial seizure disorders","volume":"46","author":"Hauser","year":"1989","journal-title":"Arch. Neurol."},{"issue":"2","key":"10.1016\/j.schres.2023.02.015_bb0195","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/WNF.0b013e318246ad34","article-title":"Treatment of catatonia with amantadine","volume":"35","author":"Hervey","year":"2012","journal-title":"Clin. Neuropharmacol."},{"issue":"7","key":"10.1016\/j.schres.2023.02.015_bb0200","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1038\/s41380-020-00889-y","article-title":"GABAB receptor, clozapine, and catatonia-a complex triad","volume":"26","author":"Hirjak","year":"2021","journal-title":"Mol. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2023.02.015_bb0205","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1093\/brain\/awac196","article-title":"Catatonia: looking back and moving forward","volume":"145","author":"Hirjak","year":"2022","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.schres.2023.02.015_bb0210","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1440-1819.2005.01331.x","article-title":"Lorazepam and diazepam rapidly relieve catatonic signs in patients with schizophrenia","volume":"59","author":"Huang","year":"2005","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.schres.2023.02.015_bb0215","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4103\/2319-4170.107162","article-title":"Rapid relief of catatonia in mood disorder by lorazepam and diazepam","volume":"36","author":"Huang","year":"2013","journal-title":"Biomed. J."},{"issue":"6","key":"10.1016\/j.schres.2023.02.015_bb0220","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.genhosppsych.2006.08.001","article-title":"Amytal interview using intravenous lorazepam in a patient with dissociative fugue","volume":"28","author":"Ilechukwu","year":"2006","journal-title":"Gen. Hosp. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2023.02.015_bb0225","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/1039856215604998","article-title":"Prevalence and symptomatology of catatonia in elderly patients referred to a consultation-liaison psychiatry service","volume":"24","author":"Kaelle","year":"2016","journal-title":"Australas Psychiatry"},{"issue":"29","key":"10.1016\/j.schres.2023.02.015_bb0230","first-page":"1296","article-title":"Treatment of anxiety neuroses in general practice using lorazepam (Tavor)","volume":"114","author":"Kaemmerer","year":"1972","journal-title":"Munch. Med. Wochenschr."},{"issue":"6","key":"10.1016\/j.schres.2023.02.015_bb0235","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1053\/seiz.1999.0309","article-title":"Ictal catatonia as a manifestation of de novo absence status epilepticus following benzodiazepine withdrawal","volume":"8","author":"Kanemoto","year":"1999","journal-title":"Seizure"},{"issue":"3","key":"10.1016\/j.schres.2023.02.015_bb0240","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/hrp\/7.3.153","article-title":"The amobarbital interview revisited: a review of the literature since 1966","volume":"7","author":"Kavirajan","year":"1999","journal-title":"Harv. Rev. Psychiatry"},{"issue":"22","key":"10.1016\/j.schres.2023.02.015_bb0245","first-page":"00334","article-title":"Catatonia is associated with higher rates of negative affect amongst patients with schizophrenia and schizoaffective disorder","volume":"S0920-9964","author":"Kline","year":"2022","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.02.015_bb0250","first-page":"135","article-title":"Zolpidem in treatment resistant adolescent catatonia: a case series","volume":"8","author":"Kumar","year":"2020","journal-title":"Scand. J. Child. Adolesc. Psychiatr. Psychol."},{"issue":"3","key":"10.1016\/j.schres.2023.02.015_bb0255","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1440-1614.2001.0905i.x","article-title":"Acute severe catatonia in a young woman with chronic schizophrenia responding to parenteral clonazepam","volume":"35","author":"Kumar","year":"2001","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2023.02.015_bb0260","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4329\/wjr.v8.i3.226","article-title":"Molecular imaging of movement disorders","volume":"8","author":"Lizarraga","year":"2016","journal-title":"World J. Radiol."},{"issue":"7","key":"10.1016\/j.schres.2023.02.015_bb0265","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/00048670701400032","article-title":"Idiopathic recurrent catatonia needs maintenance lorazepam: case report and review","volume":"41","author":"Manjunatha","year":"2007","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2023.02.015_bb0270","first-page":"52","article-title":"Favourable effect of zolpidem on catatonia","volume":"151","author":"Mastain","year":"1995","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.schres.2023.02.015_bb0275","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF02865699","article-title":"Versuche \u00fcber die biologische beeinflussung des ablaufes der schizophrenie: camphor und cardiozolkrampfe","volume":"152","author":"Meduna","year":"1935","journal-title":"Z. Ges. Neurol. Psychiatr."},{"issue":"1","key":"10.1016\/j.schres.2023.02.015_bb0280","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.mp.4001193","article-title":"Clozapine-induced reduction of glutamate transport in the frontal cortex is not mediated by GLAST and EAAC1","volume":"8","author":"Melone","year":"2003","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2023.02.015_bb0285","series-title":"The Curious History of Medicines in Psychiatry","author":"Mendelson","year":"2020"},{"issue":"6911","key":"10.1016\/j.schres.2023.02.015_bb0290","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nature01138","article-title":"Neurons in medial prefrontal cortex signal memory for fear extinction","volume":"420","author":"Milad","year":"2002","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.schres.2023.02.015_bb0295","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1037\/0033-295X.111.4.984","article-title":"\"Scared stiff\": catatonia as an evolutionary-based fear response","volume":"111","author":"Moskowitz","year":"2004","journal-title":"Psychol. Rev."},{"issue":"2","key":"10.1016\/j.schres.2023.02.015_bb0300","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0033-3182(78)71020-0","article-title":"The amytal interview: history and current uses","volume":"19","author":"Naples","year":"1978","journal-title":"Psychosomatics"},{"issue":"6","key":"10.1016\/j.schres.2023.02.015_bb0305","article-title":"Olanzapine and lorazepam used in the symptomatic management of excited catatonia secondary to anti-N-methyl-D-aspartate receptor encephalitis","volume":"12","author":"Neerukonda","year":"2020","journal-title":"Cureus"},{"issue":"7","key":"10.1016\/j.schres.2023.02.015_bb0310","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1017\/S1092852900013377","article-title":"Brain imaging in catatonia: current findings and a pathophysiologic model","volume":"5","author":"Northoff","year":"2000","journal-title":"CNS Spectr."},{"issue":"12","key":"10.1016\/j.schres.2023.02.015_bb0315","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1007\/s00702-002-0762-z","article-title":"Catatonia and neuroleptic malignant syndrome: psychopathology and pathophysiology","volume":"109","author":"Northoff","year":"2002","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"5","key":"10.1016\/j.schres.2023.02.015_bb0320","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1017\/S0140525X02000109","article-title":"What catatonia can tell us about \"top-down modulation\": a neuropsychiatric hypothesis","volume":"25","author":"Northoff","year":"2002","journal-title":"Behav. Brain Sci."},{"issue":"4","key":"10.1016\/j.schres.2023.02.015_bb0325","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/jnnp.62.4.404","article-title":"Glutamatergic dysfunction in catatonia? Successful treatment of three acute akinetic catatonic patients with the NMDA antagonist amantadine","volume":"62","author":"Northoff","year":"1997","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2023.02.015_bb0330","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41380-020-0814-5","article-title":"All roads lead to the motor cortex: psychomotor mechanisms and their biochemical modulation in psychiatric disorders","volume":"26","author":"Northoff","year":"2021","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2023.02.015_bb0335","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/1531-8257(199905)14:3<404::AID-MDS1004>3.0.CO;2-5","article-title":"Catatonia as a psychomotor syndrome: a rating scale and extrapyramidal motor symptoms","volume":"14","author":"Northoff","year":"1999","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.schres.2023.02.015_bb0340","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1136\/jnnp.67.4.445","article-title":"Decreased density of GABA-A receptors in the left sensorimotor cortex in akinetic catatonia: investigation of in vivo benzodiazepine receptor binding","volume":"67","author":"Northoff","year":"1999","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2023.02.015_bb0345","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/BF02246093","article-title":"Catatonia: short-term response to lorazepam and dopaminergic metabolism","volume":"122","author":"Northoff","year":"1995","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2023.02.015_bb0350","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.pharmthera.2015.01.005","article-title":"Clozapine and GABA transmission in schizophrenia disease models: establishing principles to guide treatments","volume":"150","author":"O'Connor","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.schres.2023.02.015_bb0355","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s00406-021-01345-w","article-title":"Resting state functional connectivity and structural abnormalities of the brain in acute retarded catatonia: an exploratory MRI study","volume":"272","author":"Parekh","year":"2022","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"3","key":"10.1016\/j.schres.2023.02.015_bb0360","doi-asserted-by":"crossref","DOI":"10.1176\/appi.neuropsych.11120367","article-title":"Treatment of catatonia with zolpidem","volume":"25","author":"Peglow","year":"2013","journal-title":"J. Neuropsychiatr. Clin. Neurosci."},{"key":"10.1016\/j.schres.2023.02.015_bb0365","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2147\/NDT.S147897","article-title":"Systematic review of catatonia treatment","volume":"14","author":"Pelzer","year":"2018","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"5","key":"10.1016\/j.schres.2023.02.015_bb0370","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0006-3223(96)00378-2","article-title":"Synergism of lorazepam and electroconvulsive therapy in the treatment of catatonia","volume":"42","author":"Petrides","year":"1997","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2023.02.015_bb0375","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ajp.2017.12.008","article-title":"The role of the GABAergic system in catatonia-insights from clozapine and benzodiazepines","volume":"32","author":"Plevin","year":"2018","journal-title":"Asian J. Psychiatr."},{"issue":"6","key":"10.1016\/j.schres.2023.02.015_bb0380","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1089\/cap.2005.15.1005","article-title":"A16-year-old girl with excited catatonia treated with low-dose oral lorazepam","volume":"15","author":"Pruett","year":"2005","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2023.02.015_bb0385","doi-asserted-by":"crossref","first-page":"391","DOI":"10.5498\/wjp.v6.i4.391","article-title":"Catatonia: our current understanding of its diagnosis, treatment and pathophysiology","volume":"6","author":"Rasmussen","year":"2016","journal-title":"World J. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2023.02.015_bb0390","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1089\/cap.2021.29207.bjc","article-title":"High-dose benzodiazepines in treatment of malignant catatonia in an adolescent: lorazepam, clonazepam, and differing efficacy","volume":"31","author":"Rice","year":"2021","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2023.02.015_bb0395","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hup.1084","article-title":"Lorazepam modulates orbitofrontal signal changes during emotional processing in catatonia","volume":"25","author":"Richter","year":"2010","journal-title":"Hum. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.schres.2023.02.015_bb0400","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1176\/ajp.145.6.764b","article-title":"Psychogenic catatonia treated with lorazepam","volume":"145","author":"Ripley","year":"1988","journal-title":"Am. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2023.02.015_bb0405","first-page":"357","article-title":"Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam","volume":"51","author":"Rosebush","year":"1990","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2023.02.015_bb0410","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00004714-199608000-00007","article-title":"Catatonia after benzodiazepine withdrawal","volume":"16","author":"Rosebush","year":"1996","journal-title":"J. Clin. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.schres.2023.02.015_bb0415","first-page":"1045","article-title":"The amytal interview in the treatment of psychogenic amnesia","volume":"36","author":"Ruedrich","year":"1985","journal-title":"Hosp. Community Psychiatry"},{"issue":"22","key":"10.1016\/j.schres.2023.02.015_bb0420","article-title":"Clozapine as a treatment for catatonia: a systematic review","volume":"S0920-9964","author":"Saini","year":"2022","journal-title":"Schizophr. Res."},{"issue":"Suppl","key":"10.1016\/j.schres.2023.02.015_bb0425","first-page":"16","article-title":"Lorazepam treatment of psychogenic catatonia: an update","volume":"49","author":"Salam","year":"1988","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2023.02.015_bb0430","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0006-3223(98)00312-6","article-title":"A double-blind comparison of lorazepam and oxazepam in psychomotor retardation and mutism","volume":"46","author":"Schmider","year":"1999","journal-title":"Biol. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2023.02.015_bb1085","first-page":"1079","article-title":"Klinische Untersuchungen mit Wy 4036 (lorazepam), einem neuartigen tranquilizer","volume":"21","author":"Schrappe","year":"1971","journal-title":"Arzneimittel-Forschung"},{"issue":"12","key":"10.1016\/j.schres.2023.02.015_bb0435","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1055\/s-2008-1068846","article-title":"Dantrolene in the treatment of life-threatening psychiatric disease pictures. A contribution to the therapy of the malignant neuroleptic syndrome and acute febrile catatonia","volume":"110","author":"Schulte-Sasse","year":"1985","journal-title":"Dtsch. Med. Wochenschr."},{"issue":"1","key":"10.1016\/j.schres.2023.02.015_bb0440","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1021\/cn400189s","article-title":"Clozapine, a fast-off-D2 antipsychotic","volume":"5","author":"Seeman","year":"2014","journal-title":"ACS Chem. Neurosci."},{"issue":"Suppl. 1","key":"10.1016\/j.schres.2023.02.015_bb0445","doi-asserted-by":"crossref","first-page":"S235","DOI":"10.4103\/0972-6748.328871","article-title":"Lorazepam challenge test: a unique clinical response in catatonia","volume":"30","author":"Seetharaman","year":"2021","journal-title":"Ind. Psychiatry J."},{"issue":"3","key":"10.1016\/j.schres.2023.02.015_bb0450","article-title":"Recognizing catatonia in medically hospitalized older adults: why it matters","volume":"3","author":"Serra-Mestres","year":"2018","journal-title":"Geriatrics (Basel)"},{"key":"10.1016\/j.schres.2023.02.015_bb0455","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.877566","article-title":"Catatonia and cognitive impairments: a systematic review","volume":"13","author":"Serrat","year":"2022","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.schres.2023.02.015_bb1050","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1021\/ja01654a033","article-title":"Some new hypnotics of the barbiturie acid series","volume":"45","author":"Shonle","year":"1923","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.schres.2023.02.015_bb0460","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fpsyt.2014.00181","article-title":"A clinical review of the treatment of catatonia","volume":"5","author":"Sienaert","year":"2014","journal-title":"Front Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2023.02.015_bb0465","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1097\/00003246-199309000-00027","article-title":"Management of lethal catatonia with dantrolene sodium","volume":"21","author":"Stemp","year":"1993","journal-title":"Crit. Care Med."},{"issue":"4","key":"10.1016\/j.schres.2023.02.015_bb1060","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF01965860","article-title":"The discovery of librium","volume":"2","author":"Sternbach","year":"1972","journal-title":"Agents Actions"},{"key":"10.1016\/j.schres.2023.02.015_bb1070","first-page":"229","article-title":"The benzodiazepine story","volume":"22","author":"Sternbach","year":"1978","journal-title":"Prog. Drug Res."},{"key":"10.1016\/j.schres.2023.02.015_bb1065","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1021\/jm00339a010","article-title":"Quinazolines and 1,4-benzodiazepines. X. Nitro-substituted 5-phenyl-1,4-benzodiazepine derivatives","volume":"6","author":"Sternbach","year":"1963","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.schres.2023.02.015_bb0470","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1176\/jnp.23.2.jnp121","article-title":"Anterior cingulate cortex: unique role in cognition and emotion","volume":"23","author":"Stevens","year":"2011","journal-title":"J. Neuropsychiatr. Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.schres.2023.02.015_bb0475","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/00006842-195803000-00003","article-title":"Shifts along the alert-repose continuum during remission of catatonic stupor with amobarbital","volume":"20","author":"Stevens","year":"1958","journal-title":"Psychosom. Med."},{"issue":"Suppl. 2","key":"10.1016\/j.schres.2023.02.015_bb0480","first-page":"9","article-title":"The effects of benzodiazepines on cognition","volume":"66","author":"Stewart","year":"2005","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2023.02.015_bb0485","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/milmed\/159.4.350","article-title":"The amytal interview in the treatment of conversion disorder: three case reports","volume":"159","author":"Stiebel","year":"1994","journal-title":"Mil. Med."},{"issue":"10","key":"10.1016\/j.schres.2023.02.015_bb0490","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1177\/0004867420968915","article-title":"Revisiting lorazepam challenge test: clinical response with dose variations and utility for catatonia in a psychiatric emergency setting","volume":"55","author":"Suchandra","year":"2021","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2023.02.015_bb0495","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/00019442-200102000-00012","article-title":"Adverse outcome with delay in identification of catatonia in elderly patients","volume":"9","author":"Swartz","year":"2001","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2023.02.015_bb0500","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/13651500500240670","article-title":"Catatonia in the elderly","volume":"9","author":"Takata","year":"2005","journal-title":"Int. J. Psychiatry Clin. Pract."},{"issue":"6","key":"10.1016\/j.schres.2023.02.015_bb0505","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/schbul\/sbz046","article-title":"The fragile brain: stress vulnerability, negative affect and GABAergic neurocircuits in psychosis","volume":"45","author":"Taylor","year":"2019","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2023.02.015_bb0510","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ajp.2016.06.002","article-title":"Maintenance lorazepam for treatment of recurrent catatonic states: a case series and implications","volume":"22","author":"Thamizh","year":"2016","journal-title":"Asian J. Psychiatr."},{"issue":"9053","key":"10.1016\/j.schres.2023.02.015_bb0515","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0140-6736(05)60139-0","article-title":"Test for catatonia with zolpidem","volume":"349","author":"Thomas","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2023.02.015_bb1025","first-page":"299","article-title":"The psycho-pharmacology of sodium amytal in catatonia","volume":"82","author":"Thorner","year":"1935"},{"issue":"8","key":"10.1016\/j.schres.2023.02.015_bb0520","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.pnpbp.2010.08.017","article-title":"Response rate of lorazepam in catatonia: a developing country's perspective","volume":"34","author":"Tibrewal","year":"2010","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2023.02.015_bb0525","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1186\/s12888-018-1925-2","article-title":"Excited catatonia in a patient with fatal pulmonary embolism and a successful treatment strategy","volume":"18","author":"Tseng","year":"2018","journal-title":"BMC Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2023.02.015_bb0530","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/YCT.0000000000000433","article-title":"The use of lorazepam and electroconvulsive therapy in the treatment of catatonia: treatment characteristics and outcomes in 60 patients","volume":"33","author":"Unal","year":"2017","journal-title":"J ECT"},{"issue":"4","key":"10.1016\/j.schres.2023.02.015_bb0535","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s002130050904","article-title":"Lorazepam for chronic catatonia: a randomized, double-blind, placebo-controlled cross-over study","volume":"142","author":"Ungvari","year":"1999","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/j.schres.2023.02.015_bb0540","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1600-0447.1994.tb01515.x","article-title":"Benzodiazepines in the treatment of catatonic syndrome","volume":"89","author":"Ungvari","year":"1994","journal-title":"Acta Psychiatr. Scand."},{"issue":"1","key":"10.1016\/j.schres.2023.02.015_bb0545","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/acps.12980","article-title":"Treatment of catatonia in autism spectrum disorders","volume":"139","author":"Wachtel","year":"2019","journal-title":"Acta Psychiatr. Scand."},{"issue":"3","key":"10.1016\/j.schres.2023.02.015_bb0550","article-title":"Rapid development of lorazepam tolerance within 48 hours in an adult with intellectual disability who presented with stuporous catatonia and refused electroconvulsive therapy","volume":"20","author":"Wahidi","year":"2018","journal-title":"Prim. Care Companion CNS Disord."},{"issue":"5","key":"10.1016\/j.schres.2023.02.015_bb0555","first-page":"972","article-title":"Resting-state hyperperfusion of the supplementary motor area in catatonia","volume":"43","author":"Walther","year":"2017","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.schres.2023.02.015_bb0560","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/schbul\/sbx091","article-title":"Aberrant hyperconnectivity in the motor system at rest is linked to motor abnormalities in schizophrenia Spectrum disorders","volume":"43","author":"Walther","year":"2017","journal-title":"Schizophr. Bull."},{"issue":"7","key":"10.1016\/j.schres.2023.02.015_bb0565","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0361-1124(79)80224-5","article-title":"The amobarbital interview","volume":"8","author":"Wettstein","year":"1979","journal-title":"JACEP"},{"issue":"9","key":"10.1016\/j.schres.2023.02.015_bb0570","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1176\/ajp.145.9.1175b","article-title":"Lorazepam for treatment of catatonic symptoms and severe psychomotor retardation","volume":"145","author":"Wetzel","year":"1988","journal-title":"Am. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2023.02.015_bb0575","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4140\/TCP.n.2013.538","article-title":"The history of benzodiazepines","volume":"28","author":"Wick","year":"2013","journal-title":"Consult. Pharm."},{"issue":"3","key":"10.1016\/j.schres.2023.02.015_bb0580","article-title":"Excited catatonia - a delayed neuropsychiatric complication of COVID-19 infection","volume":"13","author":"Zain","year":"2021","journal-title":"Cureus"},{"issue":"8","key":"10.1016\/j.schres.2023.02.015_bb0585","article-title":"Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses","volume":"8","author":"Zaman","year":"2019","journal-title":"Cochrane Database Syst. Rev."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996423000579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996423000579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T19:44:53Z","timestamp":1778701493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996423000579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":133,"alternative-id":["S0920996423000579"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2023.02.015","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lorazepam in catatonia \u2013 Past, present and future of a clinical success story","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2023.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}